Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 15, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 17, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001673776-26-000010
Filed / recorded
Apr 17, 2026, 8:12 PM UTC
Added to OQRO
Oct 2, 2026, 12:28 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
INCYTE CORP
Issuer CIK
879169
Ticker
INCY
Reporting person
Steven H Stein
Relationship
Officer
Officer title
CMO & Head of Late-Stage Dev.
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Apr 15, 2026
Transaction code
A
Shares / units
39,049
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
73,252
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 15, 2026. The earned shares will vest on the third anniversary of the July 14, 2023 grant date, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2023 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.
This includes an aggregate of 73,252 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.